Jinyao Pharmaceutical Subsidiary Receives Drug Registration Certificate for Bimatoprost Eye Drops on May 25

GateNews
According to Jinyao Pharmaceutical on May 25, its subsidiary Jinyao Heping Pharmaceutical received a drug registration certificate for Bimatoprost Eye Drops from China's National Medical Products Administration. The ophthalmic medication is indicated for lowering intraocular pressure in patients with open-angle glaucoma and ocular hypertension. The approval expands the company's ophthalmic product portfolio and strengthens its domestic pharmaceutical market presence.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments